Review article: The modern management of autoimmune hepatitis

Alimentary Pharmacology and Therapeutics

Volumn 31, Issue 8, 2010, Pages 771-787

  Yeoman, A D ^a   Longhi, M S ^a   Heneghan, M A ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEFLAZACORT; ETANERCEPT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; RITUXIMAB; TACROLIMUS; TIOGUANINE; URSODEOXYCHOLIC ACID;

ABDOMINAL PAIN; AUTOIMMUNE HEPATITIS; BONE MARROW SUPPRESSION; CANCER RISK; CLASSIFICATION ALGORITHM; CLINICAL FEATURE; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG ERYTHROCYTE LEVEL; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG MONITORING; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENTERITIS; HIRSUTISM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOPATHOGENESIS; KIDNEY DISEASE; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LONG TERM CARE; LOW DRUG DOSE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PANCREATITIS; PATHOGENESIS; PATIENT COMPLIANCE; PREGNANCY; PRIORITY JOURNAL; RECURRENT DISEASE; REGULATORY T LYMPHOCYTE; RELAPSE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SCLEROSING CHOLANGITIS; SIDE EFFECT; STEROID THERAPY; TERATOGENICITY; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ALGORITHMS; BIOLOGICAL MARKERS; FEMALE; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; PREGNANCY; PREGNANCY COMPLICATIONS; RECURRENCE; THIOGUANINE;

EID: 77949684408     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04241.x     Document Type: Review

References (128)

1. Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998 33 : 99 103.
2. Heneghan MA, McFarlane IG. Of mice and women: toward a mouse model of autoimmune hepatitis. Hepatology 2005 42 : 17 20.
3. Vento S, Garofano T, Di Perri G, Dolci L, Concia E, Bassetti D. Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals. Lancet 1991 337 : 1183 1187.
4. Vento S, Cainelli F, Renzini C, Concia E. Autoimmune hepatitis type 2 induced by HCV and persisting after viral clearance. Lancet 1997 350 : 1298 1299.
5. Le Cann P, Tong MJ, Werneke J, Coursaget P. Detection of antibodies to hepatitis E virus in patients with autoimmune chronic active hepatitis and primary biliary cirrhosis. Scand J Gastroenterol 1997 32 : 387 389.
6. Vento S, Cainelli F, Ferraro T, Concia E. Autoimmune hepatitis type 1 after measles. Am J Gastroenterol 1996 91 : 2618 2620.
7. Vento S, Guella L, Mirandola F, et al. Epstein-Barr virus as a trigger for autoimmune hepatitis in susceptible individuals. Lancet 1995 346 : 608 609.
8. Gough A, Chapman S, Wagstaff K, Emery P, Elias E. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ 1996 312 : 169 172.
9. Scully LJ, Clarke D, Barr RJ. Diclofenac induced hepatitis. 3 cases with features of autoimmune chronic active hepatitis. Dig Dis Sci 1993 38 : 744 751.
10. Alla V, Abraham J, Siddiqui J, et al. Autoimmune hepatitis triggered by statins. J Clin Gastroenterol 2006 40 : 757 761.
11. Donaldson PT. Genetics of liver disease: immunogenetics and disease pathogenesis. Gut 2004 53 : 599 608.
12. Doherty DG, Donaldson PT, Underhill JA, et al. Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis. Hepatology 1994 19 : 609 615.
13. Czaja AJ, Manns MP. The validity and importance of subtypes in autoimmune hepatitis: a point of view. Am J Gastroenterol 1995 90 : 1206 1211.
14. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999 31 : 929 938.
15. Manns M, Gerken G, Kyriatsoulis A, Staritz M, Meyer zum Buschenfelde KH. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1987 1 : 292 294.
16. Kanzler S, Weidemann C, Gerken G, et al. Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. J Hepatol 1999 31 : 635 640.
17. Wies I, Brunner S, Henninger J, et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 2000 355 : 1510 1515.
18. Ballot E, Homberg JC, Johanet C. Antibodies to soluble liver antigen: an additional marker in type 1 auto-immune hepatitis. J Hepatol 2000 33 : 208 215.
19. Manns MP, Griffin KJ, Sullivan KF, Johnson EF. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest 1991 88 : 1370 1378.
20. Kerkar N, Choudhuri K, Ma Y, et al. Cytochrome P4502D6(193-212): a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease. J Immunol 2003 170 : 1481 1489.
21. Nouri-Aria KT, Hegarty JE, Alexander GJ, Eddleston AL, Williams R. Effect of corticosteroids on suppressor-cell activity in "autoimmune" and viral chronic active hepatitis. N Engl J Med 1982 307 : 1301 1304.
22. Vento S, Hegarty JE, Bottazzo G, Macchia E, Williams R, Eddleston AL. Antigen specific suppressor cell function in autoimmune chronic active hepatitis. Lancet 1984 1 : 1200 1204.
23. Longhi MS, Ma Y, Bogdanos DP, Cheeseman P, Mieli-Vergani G, Vergani D. Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J Hepatol 2004 41 : 31 7.
24. Longhi MS, Ma Y, Mitry RR, et al. Effect of CD4+ CD25+ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis. J Autoimmun 2005 25 : 63 71.
25. Longhi MS, Hussain MJ, Mitry RR, et al. Functional study of CD4+ CD25+ regulatory T cells in health and autoimmune hepatitis. J Immunol 2006 176 : 4484 4491.
26. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Ann Rev Immunol 2004 22 : 531 562.
27. Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G. Ex vivo isolation and characterisation of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med 2001 193 : 1303 1310.
28. Ferri S, Longhi MS, De Molo C, et al. A complex immunoregulatory deficiency characterises type 1 autoimmune hepatitis. J Hepatol 2008 48 : S323.
29. Christen U, Hintermann E, Jaeckel E. New animal models for autoimmune hepatitis. Semin Liver Dis 2009 29 : 262 271.
30. Tiegs G, Hentschel J, Wendel A. A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J Clin Invest 1992 90 : 196 203.
31. Yamauchi K, Yamaguchi N, Furukawa R, et al. A murine model of acute liver injury induced by human monoclonal antibody. Hepatology 2005 40 : 687 692.
32. Kido M, Watanabe W, Okazaki T, et al. Fatal autoimmune hepatitis induced by concurrent loss of naturally arising regulatory T cells and PD-1 mediated signalling. Gastroenterology 2008 135 : 1333 1343.
33. Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993 18 : 998 1005.
34. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008 48 : 169 176.
35. Czaja AJ. Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. Hepatology 2008 48 : 1540 1548.
36. Yeoman AD, Westbrook RH, Al-Chalabi T, et al. Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group Criteria (IAIHG) in acute and chronic liver disease. Hepatology 2009 50 : 538 545.
37. Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002 36 : 479 497.
38. Miyake Y, Iwasaki Y, Terada R, et al. Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis. J Hepatol 2005 43 : 951 957.
39. Montano-Loza AJ, Carpenter HA, Czaja AJ. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol 2007 102 : 1005 1012.
40. Al-Chalabi T, Heneghan MA. Remission in autoimmune hepatitis: what is it, and can it ever be achieved? Am J Gastroenterol 2007 102 : 1013 1015.
41. Mackay IR, Weiden S, Ungar B. Treatment of active chronic hepatitis and lupoid hepatitis with 6-mercaptopurine and azothioprine. Lancet 1964 42 : 899 902.
42. Soloway RD, Summerskill WH, Baggenstoss AH, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972 63 : 820 833.
43. Kirk AP, Jain S, Pocock S, HC T, Sherlock S. Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. Gut 1980 21 : 78 83.
44. Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973 1 : 735 737.
45. Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971 40 : 159 185.
46. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995 333 : 958 963.
47. Stellon AJ, Keating JJ, Johnson PJ, McFarlane IG, Williams R. Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal. Hepatology 1988 8 : 781 784.
48. Stellon AJ, Hegarty JE, Portmann B, Williams R. Randomised controlled trial of azathioprine withdrawal in autoimmune chronic active hepatitis. Lancet 1985 1 : 668 670.
49. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992 43 : 329 339.
50. Szumlanski C, Honchel R, Scott M, Weinshilboum R. Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isoenzymes. Pharmacogenetics 1992 2 : 148 159.
51. Cooper SC, Ford LT, Berg JD, Lewis MJ. Ethnic variation of thiopurine S-methyltransferase activity: a large, prospective population study. Pharmacogenomics 2008 9 : 303 309.
52. Holme SA, Duley JA, Sanderson J, Routledge PA, Anstey AV. Erythrocyte thiopurine methyl transferase assessment prior to azathioprine use in the UK. Q J Med 2002 95 : 439 444.
53. Patel AA, Swerlick RA, McCall CO. Azathioprine in dermatology: the past, the present, and the future. J Am Acad Dermatol 2006 55 : 369 389.
54. Black AJ, McCleoud HL, Capell HA, et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998 129 : 716 718.
55. Gardiner SJ, Gearry RB, Begg EJ, Zhang M, Barclay ML. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three fold. Clin Gastroenterol Hepatol 2008 6 : 654 660.
56. Gisbert JP, Luna M, Mate J, Gonzalez-Guijarro L, Cara C, Pajares JM. Choice of azathioprine or 6- mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study. Hepatogastroenterology 2006 53 : 399 404.
57. Langley PG, Underhill J, Tredger JM, Norris S, McFarlane IG. Thiopurine methyltransferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis. J Hepatol 2002 37 : 441 447.
58. Heneghan MA, Allan ML, Bornstein JD, Muir AJ, Tendler DA. Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis. J Hepatol 2006 45 : 584 591.
59. Compagni A, Bartoli S, Buerhlen B, Fattore G, Ibarreta D, Gutierrez de Mesa E. Avoiding adverse drug reactions by pharmacogenetic testing: a systematic review of the economic evidence in the case of TPMT and AZA-induced side effects. Int J Technol Assess Health Care 2008 24 : 294.
60. Ollier WER. A prospective randomised controlled trial of azathioprine methyltransferase (TPMT) genotyping in the management of patients, prior to commencement of azathioprine. Available at: http://www.controlled-trilas.com/ mrct/trial/238433/azathioprine.
61. Dubinsky M, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000 118 : 705 713.
62. Wusk B, Kullak-Ublick GA, Rammert C, von Eckardstein A, Fried M, Rentsch KM. Therapeutic drug monitoring of thiopurine drugs in patients with inflammatory bowel disease or autoimmune hepatitis. Eur J Gastroenterol Hepatol 2004 16 : 1407 1413.
63. Rumbo C, Emerick KM, Emre S, Shneider BL. Azathioprine metabolite measurements in the treatment of autoimmune hepatitis in pediatric patients: a preliminary report. J Pediatr Gastroenterol Nutr 2002 35 : 391 398.
64. Danielsson A, Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther 1994 8 : 585 590.
65. Czaja AJ, Lindor KD. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology 2000 119 : 1312 1316.
66. Csepregi A, Rocken C, Treiber G, Malfertheiner P. Budesonide induces complete remission in autoimmune hepatitis. World J Gastroenterol 2006 12 : 1362 1366.
67. Zandieh I, Krygier D, Wong V, et al. The use of budesonide in the treatment of autoimmune hepatitis in Canada. Can J Gastroenterol 2008 22 : 388 392.
68. Rebollo Bernardez J, Cifuentes Mimoso C, Pinar Moreno A, et al. Deflazacort for long-term maintenance of remission in type I autoimmune hepatitis. Rev Esp Enferm Dig 1999 91 : 630 638.
69. Geier A, Gartung C, Dietrich CG, Wasmuth HE, Reinartz P, Matern S. Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. World J Gastroenterol 2003 9 : 2681 2685.
70. Manns MP, Woynarowski M, Kreisel W, et al. Budesonide 3mg bid in combination with azathioprine as maintenance treatment in autoimmune hepatitis - final results of a large multicenter international trial. Hepatology 2008 37 : 376A.
71. Heneghan MA, McFarlane IG. Current and novel immunosuppressive therapy for autoimmune hepatitis. Hepatology 2002 35 : 7 13.
72. Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000 33 : 371 375.
73. Devlin SM, Swain MG, Urbanski SJ, Burak KW. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol 2004 18 : 321 326.
74. Chatur N, Ramji A, Bain VG, et al. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int 2005 25 : 723 727.
75. Czaja AJ, Carpenter HA. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease. J Clin Gastroenterol 2005 39 : 819 825.
76. Wolf DC, Bojito L, Facciuto M, Lebovics E. Mycophenolate mofetil for autoimmune hepatitis. Dig Dis Sci 2009 54 : 2519 2522.
77. Inductivo-Yu I, Adams A, Gish RG, et al. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. Clin Gastroenterol Hepatol 2008 6 : 1036 1040.
78. Hlivko JT, Shiffman ML, Stravitz RT, et al. A Single Center Review of the Use of Mycophenolate Mofetil in the Treatment of Autoimmune Hepatitis. Clin Gastroenterol Hepatol 2008 6 : 1036 1040.
79. Hennes EM, Oo Y, Schramm C, et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol 2008 103 : 3063 3070.
80. Aw MM, Dhawan A, Samyn M, Bargiota A, Mieli-Vergani G. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. J Hepatol 2009 51 : 156 160.
81. Kainz A, Harabacz I, Cowlrick I, Gadgil S, Hagiwara D. Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus. Transplantation 2000 70 : 1718 1721.
82. Jain AB, Reyes J, Marcos A, et al. Pregnancy after liver transplantation with tacrolimus immunosuppression: a single center's experience update at 13 years. Transplantation 2003 76 : 827 832.
83. Christopher V, Al-Chalabi T, Richardson P, et al. Pregnancy outcome after liver transplantation: a single center experience of 71 pregnancies in 45 recipients. Liver Transpl 2006 12 : 1138 1143.
84. Van Thiel DH, Wright H, Carroll P, et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol 1995 90 : 771 776.
85. Heneghan MA, Rizzi P, McFarlane IG, Portmann B, Harrison PM. Low dose tacrolimus as treatment of severe autoimmune hepatitis: potential role in remission induction. Gut 1999 44 (Supplement 1 A61.
86. Larsen FS, Vainer B, Eefsen M, Bjerring PN, Hansen BA. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J Gastroenterol 2007 13 : 3232 3236.
87. Aqel BA, Machicao V, Rosser B, Satyanarayana R, Harnois DM, Dickson RC. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol 2004 38 : 805 809.
88. Sherman KE, Narkewicz M, Pinto PC. Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis. J Hepatol 1994 21 : 1040 1047.
89. Fernandes NF, Redeker AG, Vierling JM, Villamil FG, Fong TL. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol 1999 94 : 241 248.
90. Sciveres M, Caprai S, Palla G, Ughi C, Maggiore G. Effectiveness and safety of ciclosporin as therapy for autoimmune diseases of the liver in children and adolescents. Aliment Pharmacol Ther 2004 19 : 209 217.
91. Debray D, Maggiore G, Girardet JP, Mallet E, Bernard O. Efficacy of cyclosporin A in children with type 2 autoimmune hepatitis. J Pediatr 1999 135 : 111 114.
92. Alvarez F, Ciocca M, Canero-Velasco C, et al. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol 1999 30 : 222 227.
93. Kanzler S, Gerken G, Dienes HP, Meyer zum Buschenfelde KH, Lohse AW. Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis - report of three cases. Z Gastroenterol 1997 35 : 571 578.
94. Burak KW, Urbanski SJ, Swain MG. Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate. J Hepatol 1998 29 : 990 993.
95. Santos ES, Arosemena LR, Raez LE, O'Brien C, Regev A. Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature. Liver Int 2006 26 : 625 629.
96. Goldenberg G, Jorizzo JL. Use of etanercept in treatment of pyoderma gangrenosum in a patient with autoimmune hepatitis. J Dermatolog Treat 2005 16 : 347 349.
97. Kerkar N, Dugan C, Rumbo C, et al. Rapamycin successfully treats post-transplant autoimmune hepatitis. Am J Transplant 2005 5 : 1085 1089.
98. Czaja AJ, Carpenter HA, Lindor KD. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. Hepatology 1999 30 : 1381 1386.
99. Joshi S, Cauch-Dudek K, Wanless IR, et al. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology 2002 35 : 409 413.
100. Floreani ARE, Ferrara F, Carderi I, Caroli D, Blasone L, Baldo V. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol 2005 100 : 1516 1522.
101. De Pinho RA, Golberg CS, Lefkowitch JH. Azathioprine and the liver. Evidence favoring idiosyncratic, mixed cholestatic-hepatocellular injury in humans. Gastroenterology 1984 86 : 162 165.
102. Hegarty JE, Nouri Aria KT, Portmann B, Eddleston AL, Williams R. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology 1983 3 : 685 689.
103. Czaja AJ, Davis GL, Ludwig J, Taswell HF. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology 1984 4 : 622 627.
104. Verma S, Gunuwan B, Mendler M, Govindrajan S, Redeker A. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol 2004 99 : 1510 1516.
105. Kanzler S, Gerken G, Lohr H, Galle PR, Meyer zum Buschenfelde KH, Lohse AW. Duration of immunosuppressive therapy in autoimmune hepatitis. J Hepatol 2001 34 : 354 355.
106. Czaja AJ. Low dose corticosteroid therapy after multiple relpases of severe HBsAg-negative chronic active hepatitis. Hepatology 1990 11 : 1044 1049.
107. Cundy TF, Butler J, Pope RM, Saggar-Malik AK, Wheeler MJ, Williams R. Amenorrhoea in women with non-alcoholic liver disease. Gut 1991 32 : 202 206.
108. Heneghan MA, Norris SM, O'Grady JG, Harrison PM, McFarlane IG. Management and outcome of pregnancy in autoimmune hepatitis. Gut 2001 48 : 97 102.
109. Schramm C, Herkel J, Beuers U, Kanzler S, Galle PR, Lohse AW. Pregnancy in autoimmune hepatitis: outcome and risk factors. Am J Gastroenterol 2006 101 : 556 560.
110. Terrabuio D, Abrantes-Lemos CP, Carrilho FJ, Cancado EL. Follow-up of pregnant women with autoimmune hepatitis: the disease behavior along with maternal and fetal outcome. J Clin Gastroenterol 2009 43 : 350 356.
111. Schvarcz R, Glaumann H, Weiland O. Survival and histological resolution of fibrosis in patients with autoimmune chronic active hepatitis. J Hepatol 1993 18 : 15 23.
112. Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996 110 : 848 857.
113. Saadah OI, Smith AL, Hardikar W. Long-term outcome of autoimmune hepatitis in children. J Gastroenterol Hepatol 2001 16 : 1297 1302.
114. Floreani A, Niro G, Rosa Rizzotto E, et al. Type I autoimmune hepatitis: clinical course and outcome in an Italian multicentre study. Aliment Pharmacol Ther 2006 24 : 1051 1057.
115. Seo S, Toutounjian R, Conrad A, Blatt L, Tong MJ. Favorable outcomes of autoimmune hepatitis in a community clinic setting. J Gastroenterol Hepatol 2008 23 : 1410 1414.
116. Feld JJ, Dinh H, Arenovich T, Marcus VA, Wanless IR, Heathcote EJ. Autoimmune Hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 2005 42 : 52 63.
117. Czaja AJ, Rakela J, Ludwig J. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology 1988 95 : 448 453.
118. Feld JJ, Heathcote EJ. Epidemiology of autoimmune liver disease. J Gastroenterol Hepatol 2003 18 : 1118 1128.
119. Al-Chalabi T, Underhill J, Portmann BC, McFarlane IG, Heneghan MA. Effects of serum aspartate transaminase levels in patients with autoimmune hepatitis influence disease course and outcome. Clin Gastroenterol and Hepatol 2008 6 : 1389 1395.
120. Yeoman AD, Al-Chalabi T, Karani JB, et al. Evaluation of risk factors in the development of HCC in AIH: implications for follow-up and screening. Hepatology 2008 48 : 863 870.
121. Montano-Loza AJ, Carpenter HA, Czaja AJ. Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis. Am J Gastroenterol 2008 103 : 1944 1951.
122. Jones DB, Metcalf J, Collier J, Bassendine MF, James OF. Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes. Hepatology 1997 26 : 1138 1142.
123. Roberts M, Angus D, Bryce C, Valenta Z, Weissfeld L. Survival after liver transplantation in the United States: a disease specific analysis of the UNOS database. Liver Transpl 2004 10 : 886 897.
124. Duclos-Vallee JC, Sebagh M, Rifai K, et al. A 10 year follow up study of patients transplanted for autoimmune hepatitis: histological recurrence precedes clinical and biochemical recurrence. Gut 2003 52 : 893 897.
125. Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl 2006 12 : 1813 1824.
126. Akbar AM, Taams LS, Salmon M, Vukmanovic-Stejic M. The peripheral generation of CD4+CD25+ regulatory T cells. Immunology 2003 109 : 319 325.
127. Hoffman P, Eder R, Kiunz-Schughart LA, Andreesen R, Edinger M. Large-scale in vitro expansion of polyclonl human CD4(+)CD25 high regulatory T cells. Blood 2004 104 : 895 903.
128. Longhi MS, Meda F, Wang PH, et al. Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis. Hepatology 2008 47 : 581 591.